Skip to main content
SpringerLink
Log in

In Vivo Absorption and Disposition of Cefadroxil After Escalating Oral Doses in Wild-Type and PepT1 Knockout Mice

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

To determine the effect of PepT1 on the absorption and disposition of cefadroxil, including the potential for saturable intestinal uptake, after escalating oral doses of drug.

Methods

The absorption and disposition kinetics of [3H]cefadroxil were determined in wild-type and PepT1 knockout mice after 44.5, 89.1, 178, and 356 nmol/g oral doses of drug. The pharmacokinetics of [3H]cefadroxil were also determined in both genotypes after 44.5 nmol/g intravenous bolus doses.

Results

PepT1 deletion reduced the area under the plasma concentration-time profile (AUC0-120) of cefadroxil by 10-fold, the maximum plasma concentration (Cmax) by 17.5-fold, and increased the time to reach a maximum plasma concentration (Tmax) by 3-fold. There was no evidence of nonlinear intestinal absorption since AUC0-120 and Cmax values changed in a dose-proportional manner. Moreover, the pharmacokinetics of cefadroxil were not different between genotypes after intravenous bolus doses, indicating that PepT1 did not affect drug disposition. Finally, no differences were observed in the peripheral tissue distribution of cefadroxil (i.e., outside gastrointestinal tract) once these tissues were corrected for differences in perfusing blood concentrations.

Conclusions

The findings demonstrate convincingly the critical role of intestinal PepT1 in both the rate and extent of oral administration for cefadroxil and potentially other aminocephalosporin drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008;60:543–85.

    Article  PubMed  CAS  Google Scholar 

  2. Rubio-Aliaga I, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica. 2008;38:1022–42.

    Article  PubMed  CAS  Google Scholar 

  3. Smith DE, Clemençon B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med. 2013;34:323–36.

    Article  PubMed  CAS  Google Scholar 

  4. Yamashita T, Shimada S, Guo W, Sato K, Kohmura E, Hayakawa T, et al. Cloning and functional expression of a brain peptide/histidine transporter. J Biol Chem. 1997;272:10205–11.

    Article  PubMed  CAS  Google Scholar 

  5. Sakata K, Yamashita T, Maeda M, Moriyama Y, Shimada S, Tohyama M. Cloning of a lymphatic peptide/histidine transporter. Biochem J. 2001;356(Pt 1):53–60.

    Article  PubMed  CAS  Google Scholar 

  6. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15:1154–9.

    Article  PubMed  CAS  Google Scholar 

  7. Bretschneider B, Brandsch M, Neubert R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999;16:55–61.

    Article  PubMed  CAS  Google Scholar 

  8. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci. 2002;23:434–40.

    Article  PubMed  CAS  Google Scholar 

  9. Buck RE, Price KE. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977;11:324–30.

    Article  PubMed  CAS  Google Scholar 

  10. Tanrisever B, Santella PJ. Cefadroxil: a review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs. 1986;32 Suppl 3:1–16.

    Article  PubMed  CAS  Google Scholar 

  11. Marino EL, Dominguez-Gil A, Muriel C. Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil. Int J Clin Pharmacol Ther Toxicol. 1982;20:73–7.

    PubMed  CAS  Google Scholar 

  12. Tsuji A, Nakashima E, Kagami I, Yamana T. Intestinal absorption mechanism of amphoteric beta-lactam antibiotics I: comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine. J Pharm Sci. 1981;70:768–72.

    Article  PubMed  CAS  Google Scholar 

  13. de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP. Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012;40:515–21.

    Article  PubMed  Google Scholar 

  14. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, Brosius 3rd FC. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol. 1999;276:F658–65.

    PubMed  CAS  Google Scholar 

  15. Shen H, Smith DE, Keep RF, Brosius 3rd FC. Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharm. 2004;1:248–56.

    Article  PubMed  CAS  Google Scholar 

  16. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 2002;82:193–201.

    Article  PubMed  CAS  Google Scholar 

  17. Ming X, Thakker DR. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem Pharmacol. 2010;79:455–62.

    Article  PubMed  CAS  Google Scholar 

  18. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signaling molecules. Trends Pharmacol Sci. 2008;29:200–7.

    Article  PubMed  CAS  Google Scholar 

  19. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36.

    Article  PubMed  CAS  Google Scholar 

  20. Sánchez-Picó A, Peris-Ribera JE, Toledano C, Torres-Molina F, Casabó VG, Martín-Villodre A, et al. Non-linear intestinal absorption kinetics of cefadroxil in the rat. J Pharm Pharmacol. 1989;41:179–85.

    Article  PubMed  Google Scholar 

  21. Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF. Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol. 1991;41:179–83.

    Article  PubMed  CAS  Google Scholar 

  22. Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos. 2007;35:1209–16.

    Article  PubMed  Google Scholar 

  23. Posada MM, Smith DE. Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res. 2013;30:1017–25.

    Article  PubMed  CAS  Google Scholar 

  24. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, Hillgren KM. Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm. 2008;5:1122–30.

    Article  PubMed  CAS  Google Scholar 

  25. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Philadelphia: Wolters Kluwer; 2011.

    Google Scholar 

  26. Jappar D, Wu SP, Hu Y, Smith DE. Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos. 2010;38:1740–6.

    Article  PubMed  CAS  Google Scholar 

  27. Jappar D, Hu Y, Smith DE. Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos. 2011;39:2250–7.

    Article  PubMed  CAS  Google Scholar 

  28. La Rosa F, Ripa S, Prenna M, Ghezzi A, Pfeffer M. Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob Agents Chemother. 1982;21:320–2.

    Article  PubMed  Google Scholar 

  29. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol. 2008;60:63–70.

    Article  PubMed  CAS  Google Scholar 

  30. Yang B, Smith DE. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos. 2013;41:608–14.

    Article  PubMed  CAS  Google Scholar 

  31. Ma K, Hu Y, Smith DE. Influence of fed-fasted state on intestinal PEPT1 expression and in vivo pharmacokinetics of glycylsarcosine in wild-type and Pept1 knockout mice. Pharm Res. 2012;29:535–45.

    Article  PubMed  CAS  Google Scholar 

  32. García-Carbonell MC, Granero L, Torres-Molina F, Aristorena JC, Chesa-Jiménez J, Plá-Delfina JM, et al. Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos. 1993;21:215–7.

    PubMed  Google Scholar 

  33. Mariño EL, Dominguez-Gil A. Influence of dose on the pharmacokinetics of cefadroxil. Eur J Clin Pharmacol. 1980;18:505–9.

    Article  PubMed  Google Scholar 

  34. Barbhaiya RH. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos. 1996;17:319–30.

    Article  PubMed  CAS  Google Scholar 

  35. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther. 2005;315:240–7.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM035498] (to D.E.S.).

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA

    Maria M. Posada & David E. Smith

  2. Department of Pharmaceutical Sciences, University of Michigan, 4742C Medical Sciences II, 1150 W. Medical Center Drive, Ann Arbor, Michigan, 48109-5633, USA

    David E. Smith

Authors
  1. Maria M. Posada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David E. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Posada, M.M., Smith, D.E. In Vivo Absorption and Disposition of Cefadroxil After Escalating Oral Doses in Wild-Type and PepT1 Knockout Mice. Pharm Res 30, 2931–2939 (2013). https://doi.org/10.1007/s11095-013-1168-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-013-1168-3

KEY WORDS

Search

Navigation